Industry sponsored sessions


Sunday 06 May 13:30-15:00
Intensive reduction of LDL to reduce cv risk: where do we stand?

  • Alberico L. Catapano, Italy

LDL is causal to CVD

Chris Packard, Glasgow, UK

PCSK9 inhibition the clinical evidence

Peter Sever, London, United Kingdom

A contemporary approach to dyslipidaemias, PCSK9 inhibition

Ulf Landmesser, Berlin, Germany


Educational Symposium sponsored by AMGEN

Saturday 05 May 14:30-16:00
The landmark trial-based evidence and rationale for PCSK9 inhibition to prevent and treat atherosclerosis cardiovascular disease ASCVD: from investigation to intervention

  • Gabriel P. Steg, France
  • Deepak Bhatt, USA

The mandate for improving residual CVD risk reduction in patients with persistently elevated LDL-C: What unmet needs still exist among high risk patients across the continuum of ASCVD care? What new outcome - substantiated therapies are in our toolkit?

Deepak Bhatt, Boston, USA

What do recent landmark, cardiovascular outcome trials evaluating PCSK9 inhibition in high risk patient populations teach us? How safe and effective are PCSK9 inhibitors and in whom and when should they be deployed?

Gabriel P. Steg, Paris, France

ESC/EAS and ACC/ECDP update guidelines update for LDL-C lowering in ASCVD: the role of non-statin therapies for ASCVD reduction in ACS and diabetic patients. Addressing statin intolerance, poor target LDL goal attainment and resistence syndromes

J. Wouter Jukema, Leiden, The Netherlands

Getting real world and “hands on” in patients with elevated LDL-C and associated high risk features for ASCVD— interactive case management sessions

Gabriel P. Steg, Paris, France

J. Wouter Jukema, Leiden, The Netherlands

Deepak Bhatt, Boston, USA

Program chair’s 2018 and beyond summary vision statement the data is in: overcoming institutional, cost, and clinical inertia barriers to deployment of non-statin therapies for optimizing treatment and prevention of ASCVD.

Deepak Bhatt, Boston, USA




Educational Symposium sponsored by Sanofi and Regeneron Pharmaceuticals


Sunday 06 May 08:00-08:45
The latest practical considerations in treating blood cholesterol levels in coronary patients

  • Heinz Drexel, Austria

LDL-C guidelines targets & current treatment gap

Heinz Drexel, Feldkirch, Austria

State of the art lipid lowering combination therapies

Peter Toth, Peoria, USA

Current concepts and their use in clinical practice

Alberico L. Catapano, Milan, Italy

Q&A-roundtable discussion


Breakfast Symposium sponsored by MSD

Monday 07 May 08:00-08:45
Challenging the current treatment paradigm in patients at very high CV risk

  • Alberico L. Catapano, Italy

Secondary prevention: can we go further?

Erik S. Stroes, Amsterdam, The Netherlands

PCSK9 inhibitors in CV risk: from data to clinical practice

Ulf Landmesser, Berlin, Germany


Breakfast Symposium sponsored by AMGEN


Sunday 06 May 13:30-14:15
Hypercholesterolemia: what is hidden behind the smoke screen of inherited lipid disorders?

Pathways to personalized therapy

M. John Chapman, Paris, France

How to avoid the differential diagnostic odyssey

Mafalda Bourbon, Lisbon, Portugal


Special Lecture sponsored by ALEXION

Monday 07 May 13:30-14:15
High-intensity pitavastatin therapy further improves clinical outcomes in Japanese patients with stable coronary artery disease. Evidence from REAL-CAD

  • Borge Nordestgaard, Denmark

Evidence from REAL-CAD

Takeshi Kimura, Kyoto, Japan

Closing remarks

Borge Nordestgaard, Copenhagen, Denmark


Special Lecture sponsored by KOWA